James E. Wagner Cultivation Corporation

OTC: JWCAF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Kitchener, ONReports USD

#812 of 1,394 Healthcare companies by revenuetop-decile growth

EA Score

——

FH —DQ —GM —SS 41

v0.1 · 5/100 weight · pillars only

↑ revenue growth (YoY), workforce scale · ↓ disclosure history, market scale

Methodology →

Revenue TTM

$1.9M

Rev growth YoY (TTM)

+310.1%

Net income (FY)

-$5.3M

Employees

160

Market cap

$10.9k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$1.6M2.1M CAD2019

Net income-$5.3M-7.0M CAD2019

Operating income-$7.0M-9.2M CAD2019

Total assets$16.5M21.9M CAD2019

Liabilities$7.9M10.5M CAD2019

Equity$8.6M11.4M CAD2019

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

James E. Wagner Cultivation Corporation booked $1.6M in FY2019 revenue, growing 3478% year over year — faster than 98% of Healthcare companies we track, at a -327.9% net margin.

Peers · Healthcare

Manhattan Scientifics, Inc.——GeneLink, Inc.——VIA Pharmaceuticals, Inc.——Ehouse Global, Inc.——

Key facts

CEONathaniel Woodworth

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersKitchener, ON

ExchangeOTC: JWCAF

Employees160

IPO date2018-06-25

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.